[1] [1] GALE N, POLJAK M, ZIDAR N. Update from the 4th edition of the World Health Organization classification of head and neck tumours: what is new in the 2017 WHO blue book for tumours of the hypopharynx, larynx, trachea and parapharyngeal space[J]. Head Neck Pathol, 2017, 11(1): 23-32. DOI: 10.1007/s12105-017-0788-z.

[2] [2] ZHAO Q, WEI J, ZHANG C, et al. Large-cell neuroendocrine carcinoma of nasal cavity and paranasal sinuses after successful curative therapy: a case report and literature review[J]. Onco Targets Ther, 2019, 12: 2975-2980. DOI: 10.2147/ott.s195052.

[3] [3] TRAVIS W D, LINNOILA R I, TSOKOS M G, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases[J]. Am J Surg Pathol, 1991, 15(6): 529-553. DOI: 10.1097/00000478-199106000-00003.

[4] [4] RAI Y, NISHIOKA H, HARA T. Large cell neuroendocrine carcinoma in the sinonasal cavity with large intracranial extension treated with endonasal endoscopic and transcranial combined surgery: a case report[J]. NMC Case Rep J, 2021, 8(1): 485-491. DOI: 10.2176/nmccrj.cr.2020-0424.

[5] [5] PATEL T D, VAZQUEZ A, DUBAL P M, et al. Sinonasal neuroendocrine carcinoma: a population-based analysis of incidence and survival[J]. Int Forum Allergy Rhinol, 2015, 5(5): 448-453. DOI: 10.1002/alr.21497.

[7] [7] LAHMA J, HEJJOUJI R, GICQUEL P, et al. Large cell neuroendocrine carcinoma of the nasal cavity: an extremely rare and new distinct entity[J]. Pan Afr Med J, 2018, 30: 188. DOI: 10.11604/pamj.2018.30.188.14992.

[8] [8] THOMPSON E D, STELOW E B, MILLS S E, et al. Large cell neuroendocrine carcinoma of the head and neck: a clinicopathologic series of 10 cases with an emphasis on HPV status[J]. Am J Surg Pathol, 2016, 40(4): 471-478. DOI: 10.1097/pas.0000000000000580.

[9] [9] WU W, GAN P, XU Q, et al. Neuroendocrine carcinoma of the nasal cavity with Epiphora as the first symptom: a case report[J]. Medicine (Baltimore), 2020, 99(49): e23502. DOI: 10.1097/md.0000000000023502.

[10] [10] DUAN K, METE O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers[J]. Cancer Cytopathol, 2016, 124(12): 871-884. DOI: 10.1002/cncy.21765.

[11] [11] ROOPER L M, BISHOP J A, WESTRA W H. INSM1 is a sensitive and specific marker of neuroendocrine differentiation in head and neck tumors[J]. Am J Surg Pathol, 2018, 42(5): 665-671. DOI: 10.1097/pas.0000000000001037.

[12] [12] DOGAN S, VASUDEVARAJA V, XU B, et al. DNA methylation-based classification of sinonasal undifferentiated carcinoma[J]. Mod Pathol, 2019, 32(10): 1447-1459. DOI: 10.1038/s41379-019-0285-x.

[13] [13] BARI M F, BROWN H, NICHOLSON A G, et al. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas[J]. Histopathology, 2014, 64(4): 547-556. DOI: 10.1111/his.12278.

[14] [14] FELIX-RAVELO M, BEY A, AROUS F, et al. Relationship between 18FDG-PET and different types of sinonasal malignancies[J]. Acta Otolaryngol, 2017, 137(2): 191-195. DOI: 10.1080/00016489.2016.1219917.

[15] [15] VAN DER LAAN T P, PLAAT B E, VAN DER LAAN B F, et al. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: a meta-analysis of 436 reported cases[J]. Head Neck, 2015, 37(5): 707-715. DOI: 10.1002/hed.23666.